Carnot Curie Cancer

Curie Cancer is built on the expertise of Institut Curie (3200 people), a leading comprehensive cancer center in Europe and world-renowned hospital. 
Curie Cancer offers industrial partners the ability to setup research collaborations from early discovery (cognitive research) to the most advanced research stages (clinical research).

Economic sectors

Beauty products
Health technologies
Pharmaceuticals
Key figures
Fermer

Key figures

Permanent staff (full-time equivalent)
891
PhD Students
179
Global budget
104,9 M€
Partnership
incomes with industry
12,7 M€
Contact
Fermer

Contact

Institut Curie
Technology Transfer & Industrial Partnerships
26 rue d'Ulm
75248 Paris Cedex 5
France

Amaury Martin
+33 (0)1 56 24 55 80

Géraldine Gubitta-Wane
+33 (0)1 56 24 55 84
 

Email contact

Presentation

From therapeutic target… to clinical validation

   
  © Noak / Le Bar Floréal / Institut Curie  

The model of Marie Curie

  • Marie Curie, founder of Institut Curie, was attached to the seamless continuity from fundamental and clinical research to patient care. Curie Cancer maintains these dynamics and puts together leading teams in cognitive, translational and clinical research.
  • Curie Cancer offers tailor-made collaborative research projects to industrial partners, based on the internal expertise of its teams as well as the capabilities of its advanced technical platforms.
  • Led by numerous professionals from the pharmaceutical and/or biotechnology industry, Curie Cancer can thus set up collaborations that meet the needs of industrial partners.

Target markets

  • Health technologies
  • Pharmaceuticals
  • Cosmetics

Expertise and know-how

  • Cell and Molecular Biology
  • Immunology
  • Epigenetics
  • Radiobiology
  • Microfluidics
  • Bioinformatics
  • Biophysics
  • Medicinal chemistry
  • Imaging
  • Clinical Trials
  • Radiotherapy

Examples of collaborative projects with industrial partners

  • Identification and validation of therapeutic targets
  • Evaluation of anticancer activity in human primary xenograft models
  • Identification of biomarkers
  • Characterization of the mode of action of products under development
  • Medicinal chemistry
  • Monoclonal antibody screening
  • Pharmacokinetics
  • Clinical studies in phase I, II or III for several types of cancer

      
   © Noak / Le Bar Floréal / Institut Curie / © Arnaud Echard / CNRS / Institut Curie

Examples of technological platforms 

  • Bank of tumor tissus
  • Xenografts in nude mice
  • Transgenic mice, zebra-fish…
  • High-throughput sequencing
  • High-throughput phenotypic screening
  • Cyclotron to produce radioisotope with ultra-short half-life
  • Imaging, Bioinformatics, Omics...